These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33130959)

  • 1. Helping Clinicians to Detect ODD in Children with ADHD in Clinical Settings.
    Tahillioğlu A; Dogan N; Ercan ES; Rohde LA
    Psychiatr Q; 2021 Jun; 92(2):821-832. PubMed ID: 33130959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An open trial on effectiveness of parent training in children with comorbid attention deficit hyperactivity disorder and oppositional defiant disorder].
    Liu J; Wang YF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 39(3):310-4. PubMed ID: 17572790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bifactor latent structure of attention-deficit/hyperactivity disorder (ADHD)/oppositional defiant disorder (ODD) symptoms and first-order latent structure of sluggish cognitive tempo symptoms.
    Lee S; Burns GL; Beauchaine TP; Becker SP
    Psychol Assess; 2016 Aug; 28(8):917-28. PubMed ID: 26502205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does oppositional defiant disorder have temperament and psychopathological profiles independent of attention deficit/hyperactivity disorder?
    Kim HW; Cho SC; Kim BN; Kim JW; Shin MS; Yeo JY
    Compr Psychiatry; 2010; 51(4):412-8. PubMed ID: 20579516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder.
    Golubchik P; Shalev L; Tsamir D; Manor I; Weizman A
    Int Clin Psychopharmacol; 2019 May; 34(3):138-142. PubMed ID: 30640748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROC Analyses of Relevant Conners 3-Short Forms, CBCL, and TRF Scales for Screening ADHD and ODD.
    Gomez R; Vance A; Watson S; Stavropoulos V
    Assessment; 2021 Jan; 28(1):73-85. PubMed ID: 31535569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder.
    Gau SS; Ni HC; Shang CY; Soong WT; Wu YY; Lin LY; Chiu YN
    Aust N Z J Psychiatry; 2010 Feb; 44(2):135-43. PubMed ID: 20113302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor structure and cultural factors of disruptive behaviour disorders symptoms in Italian children.
    Zuddas A; Marzocchi GM; Oosterlaan J; Cavolina P; Ancilletta B; Sergeant J
    Eur Psychiatry; 2006 Sep; 21(6):410-8. PubMed ID: 16356689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Impairment on the Prevalence and Comorbidities of Attention Deficit Hyperactivity Disorder in a National Survey: Nation-Wide Prevalence and Comorbidities of ADHD.
    Ercan ES; Unsel-Bolat G; Tufan AE; Karakoc Demirkaya S; Bilac O; Celik G; Kılıç BG; Akyol Ardic U; Yalin Sapmaz S; Aksu H; Yolga Tahiroglu A; Karacetin G; Tural U; Aktepe E; Rodopman Arman A; Başgül S; Coşkun M; Dursun OB; Durukan İ; Perdahli Fiş N; Gençoğlan S; Gökçen C; Sarı Gokten E; Görker I; Görmez V; Yıldız Gündoğdu Ö; Hesapçioğlu ST; Kandemir H; Mutluer T; Nasiroğlu S; Özcan Ö; Şahin N; Toros F; Perçinel Yazici İ; Yazici KU; Yulaf Y; Yüksel T; Bilgic A; Altun H; Akdemir D; Mazlum B; Çakın Memik N; Foto Özdemir D; Üneri Ö; Ünal F
    J Atten Disord; 2022 Mar; 26(5):674-684. PubMed ID: 34032170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention-deficit-hyperactivity disorder with and without oppositional defiant disorder in 3- to 7-year-old children.
    Kadesjö C; Hägglöf B; Kadesjö B; Gillberg C
    Dev Med Child Neurol; 2003 Oct; 45(10):693-9. PubMed ID: 14515941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in the effects of oppositional behavior on teacher ratings of ADHD symptoms.
    Jackson DA; King AR
    J Abnorm Child Psychol; 2004 Apr; 32(2):215-24. PubMed ID: 15164862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive function in attention-deficit-hyperactivity disorder with and without comorbid disruptive behaviour disorders.
    Barnett R; Maruff P; Vance A
    Aust N Z J Psychiatry; 2009 Aug; 43(8):722-30. PubMed ID: 19629793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence.
    Sobanski E; Banaschewski T; Asherson P; Buitelaar J; Chen W; Franke B; Holtmann M; Krumm B; Sergeant J; Sonuga-Barke E; Stringaris A; Taylor E; Anney R; Ebstein RP; Gill M; Miranda A; Mulas F; Oades RD; Roeyers H; Rothenberger A; Steinhausen HC; Faraone SV
    J Child Psychol Psychiatry; 2010 Aug; 51(8):915-23. PubMed ID: 20132417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inattention, hyperactivity, oppositional-defiant symptoms and school failure.
    Serra-Pinheiro MA; Mattos P; Regalla MA; de Souza I; Paixão C
    Arq Neuropsiquiatr; 2008 Dec; 66(4):828-31. PubMed ID: 19099120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and validity of teacher-rated symptoms of oppositional defiant disorder and conduct disorder in a clinical sample.
    Ise E; Görtz-Dorten A; Döpfner M
    Psychopathology; 2014; 47(5):312-8. PubMed ID: 24993973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptive behavior disorders?
    Connor DF; Doerfler LA
    J Atten Disord; 2008 Sep; 12(2):126-34. PubMed ID: 17934178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.